2 recruiting, 1 active not recruiting, 1 not yet recruiting. 3 Phase 2, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 2, Active not recruiting 1 |
| Phase 1 | 1 | Not yet recruiting 1 |
Follow Macupatide: new trials by email Literature Review of Macupatide trials Research Report on Macupatide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Macupatide (LY3532226) in Participants With Obesity or Overweight Without Type 2 Diabetes Macupatide, Eloralintide, Placebo - Obesity, Overweight | Phase 1 | Not yet recruiting | Eli Lilly and Company | 60 | 2026-10-01 | 2026-08-14 |
| A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight Macupatide, Eloralintide, Placebo - Overweight, Obesity | Phase 2 | Recruiting | Eli Lilly and Company | 400 | 2026-05-15 | 2026-10-08 |
| A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes Macupatide, Eloralintide, Macupatide Placebo - Obesity, Overweight | Phase 2 | Active not recruiting | Eli Lilly and Company | 200 | 2025-10-16 | 2026-10-09 |
| A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight LY3305677, LY3841136, Tirzepatide - Obesity, Overweight | Phase 2 | Recruiting | Eli Lilly and Company | 1481 | 2023-11-17 | 2026-10-07 |
Obesity (4) · Overweight (4) · Diabetes Mellitus, Type 2 (1)
United States (3) · Argentina (2) · Australia (1) · Japan (1) · Puerto Rico (1)